Business
Celcuity To Present at Upcoming Needham and Stifel Investor Conferences
MINNEAPOLIS, April 01, 2025 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted
About this update from Celcuity Inc.
MINNEAPOLIS , April 01, 2025 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced that Brian Sullivan , Chief Executive Officer, and Co-founder of Celcuity , will present and be available for one-on-one investor meetings at the following investor conferences: A fireside chat at the Stifel 2025 Virtual Targeted Oncology Forum at 10:00 a.m. ET on Wednesday, April 9, 2025 . A live webcast will be available using this weblink: https://wsw.com/webcast/stifel99/celc/2065375 ; and A fireside chat at the 24th Annual Needham Virtual Healthcare Conference at 11:00 a.m. ET on Thursday, April 10, 2025 . A live webcast will be available using this weblink: https://wsw.com/webcast/needham146/celc/2212811 . Alternatively, the live webcasts will be accessible from the Investors section of the company's website at https://ir.celcuity.com/events-presentations/ with a replay available shortly after the live events. About Celcuity Celcuity is a clinical-stage biotechnology company pursuing development of targeted therapies for treatment of multiple solid tumor indications. The company's lead therapeutic candidate is gedatolisib, a potent, pan-PI3K and mTORC1/2 inhibitor that comprehensively blockades the PI3K/AKT/mTOR (“PAM”) pathway. Its mechanism of action and pharmacokinetic properties are differentiated from other currently approved and investigational therapies that target PI3Kα, AKT, or mTORC1 alone or together. A Phase 3 clinical trial, VIKTORIA-1, evaluating gedatolisib in combination with fulvestrant with or without palbociclib in patients with HR+/HER2- advanced breast cancer is currently enrolling patients. More detailed information about the VIKTORIA-1 study can be found at ClinicalTrials.gov . A Phase 1b/2 clinical trial, CELC-G-201, evaluating gedatolisib in combination with darolutamide in patients with metastatic castration resistant prostate cancer, is ongoing. A Phase 3 clinical trial, VIKTORIA-2, evaluating gedatolisib plus a CDK4/6 inhibitor and fulvestrant as first-line treatment for patients with HR+/HER2- advanced breast cancer is currently recruiting patients. Celcuity is headquartered in Minneapolis . Further information about Celcuity can be found at www.celcuity.com . Follow us on LinkedIn and Twitter . View source version of release on GlobeNewswire.com Contacts: Celcuity Inc. Brian Sullivan , [email protected] Vicky Hahne , [email protected] (763) 392-0123 ICR Healthcare Patti Bank , [email protected] (415) 513-1284 Source: Celcuity Inc.